Search

for
Search:

Did you mean EGFR inhibitors?

GlossaryEGFR inhibitors

block cell growth signals to treat certain cancers

EGFR inhibitors, also known as Epidermal Growth Factor Receptor inhibitors, are a class of drugs that block the activity of the EGFR, a protein on the surface of cells that helps them grow and divide. By inhibiting this receptor, these drugs can slow down or stop the growth of certain types of cancer cells that rely on EGFR for proliferation. They are commonly used in the treatment of cancers such as non-small cell lung cancer and colorectal cancer.

Related Terms

Sort by

Research

30 / 1000+ results

Classification and Management of Skin, Hair, Nail, and Mucosal Side Effects of Epidermal Growth Factor Receptor Inhibitors

research Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors

138 citations , February 2007 in “European journal of cancer”

EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.

research Persistent hair growth during treatment with the EGFR inhibitor erlotinib

39 citations , March 2009 in “Dermatology Online Journal”

Erlotinib can cause persistent excessive hair growth.

Semiology of Skin Toxicity Associated with Epidermal Growth Factor Receptor Inhibitors

research Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

38 citations , February 2012 in “Supportive Care in Cancer”

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

research Cutaneous side-effects of EGFR inhibitors and their management.

38 citations , January 2011 in “PubMed”

EGFR inhibitors often cause skin issues like acne and dryness, which can be managed with specific treatments.

research Erosive Pustular Dermatosis of the Scalp-Like Eruption due to Gefitinib: Case Report and Review of the Literature of Alopecia Associated with EGFR Inhibitors

36 citations , January 2012 in “Dermatology”

Stopping gefitinib improved scalp condition in a woman with lung cancer.

research The management of EGFR inhibitor adverse events: a case series and treatment paradigm

32 citations , January 2012 in “International Journal of Dermatology”

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management

29 citations , September 2017 in “Oncology and therapy”

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

research Rash from EGFR inhibitors: Opportunities and challenges for palliation

18 citations , July 2008 in “Current Oncology Reports”

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

research EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines

7 citations , January 2023 in “Anti-Cancer Drugs”

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers

3 citations , January 2011 in “Annals of Dermatology”

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

research 566 Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity

July 2024 in “Journal of Investigative Dermatology”

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

PRIDE Complex: Papulopustules, Paronychia, Hair Growth Abnormalities, Itching, and Dryness Due to EGFR Inhibitors

research PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)

August 2025 in “JEADV Clinical Practice”

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

PRIDE Syndrome: A Practical Way to Identify Adverse Skin Effects of EGFR Inhibitors

research Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR

October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana”

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

research 422 Human hair follicles express PD-L1, whose expression is down-regulated by EGFR and MEK inhibitors ex vivo. A potential mechanism for EGFR inhibitor induced sterile folliculitis

September 2019 in “Journal of Investigative Dermatology”

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

research MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?

June 2011 in “Oncology times”

Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.

Cutaneous and Mucosal Side Effects of New Anticancer Drugs: EGF-R Inhibitors, Tyrosine Kinase Inhibitors, and Mitotic Spindle Stabilizers

research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique

January 2011

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

research 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo

July 2022 in “Journal of Investigative Dermatology”

research Depletion of Gsdma1/2/3 alleviates PMA-induced epidermal hyperplasia by inhibiting the EGFR–Stat3/Akt pathway

6 citations , December 2023 in “Journal of Molecular Cell Biology”

Removing Gsdma1/2/3 genes reduces skin cell overgrowth by blocking a specific cell pathway.

research The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome

90 citations , August 2006 in “British Journal of Dermatology”

PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.

research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

68 citations , January 2014 in “Dermatology research and practice”

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

research Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib

57 citations , August 2006 in “Journal of the American Academy of Dermatology”

Gefitinib can cause hair loss without scarring.

research EGFR signaling is required for regenerative proliferation in the cochlea: Conservation in birds and mammals

53 citations , January 2012 in “Developmental Biology”

EGFR signaling is essential for ear cell regeneration in both birds and mammals.

research Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex

43 citations , January 2014 in “Indian Journal of Dermatology”

EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.

research A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib

33 citations , June 2009 in “Journal of Cutaneous Pathology”

Erlotinib can cause nonscarring hair loss and itchy skin.

research IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes

32 citations , December 2019 in “The Journal of clinical investigation/The journal of clinical investigation”

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

research Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities

22 citations , March 2017 in “Journal of the Formosan Medical Association”

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

research Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Acneiform Eruption with Topical Recombinant Human Epidermal Growth Factor

19 citations , January 2012 in “Dermatology”

Topical human epidermal growth factor may effectively treat acne caused by cancer medication.